The Allie and Kaleigh Fasanella Story

Featured News

January 20, 2026Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

October 28, 2025Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study

All News

Subscribe

Get Netherton Syndrome Updates from Quoin

This website does not provide medical advice and is for educational purposes only. Quoin Pharmaceuticals a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases NethertonNow and associated logo are trademarks of Quoin Pharmaceuticals.

All information, documentation, data, photographs, and other content herein is the property of Quoin Pharmaceuticals, Inc. and its affiliates, and is protected by worldwide copyright laws. You may use this content only for your personal use for non- commercial purposes, and no modification or further reproduction of the content is permitted. The content may otherwise not be copied or used in any way without the express written permission of Quoin Pharmaceuticals, Inc.

Privacy Policy Sitemap